Medrio eConsent Is Live – and Already Enhancing Site Operations

After months of development, extensive beta testing, and lots of user feedback, we’ve reached a milestone moment here at Medrio:

Medrio eConsent, our tablet application enhancing electronic informed consent in clinical trials, is now live!

Last week, the platform officially became available on Google Play. Getting to this moment was a collaborative effort, with Medrio customers providing firsthand user insight that helped us ensure the final product is aligned with the consent needs of today’s clinical researchers and patients. We’re excited to note that these joint efforts have paid off: Several Medrio customers have already signed up to use the platform in their upcoming trials.

Not long ago on the blog, we discussed the implications of eConsent on organizations’ site operations and patient engagement efforts, as well as the regulatory background of this exciting moment for the clinical research industry. Now, let’s dive into the product itself. What does Medrio eConsent look like? Whom does it serve? And what can organizations achieve with it?

Medrio eConsent and clinical trial patients

As we discussed in our earlier post, eConsent is more than just a source of efficiency for clinical researchers. It’s a patient engagement tool as well. With supplementary graphics, videos, FAQ documents, and quiz modules making the consent process less jargon-heavy and more layperson-friendly, comprehension becomes much less cumbersome. Patients can more easily understand exactly what will be expected of them during the trial, making it much less likely that they’ll drop out due to an unpleasant surprise stemming from a misunderstanding during consent.

Videos and other supplementary materials enhance patient comprehension.

This leads to stronger patient retention rates, which translates to benefits for the organizations conducting the trial. A recent study placed the per-patient cost of consent at $1,700 – money that goes right out the window every time a patient leaves a study before completion.

So what’s in it for sponsors, CROs, and sites?

From the organizational perspective, the fundamental benefits of Medrio eConsent don’t look so different from the benefits of our eSource application. By eliminating paper forms from the consenting process, organizations maximize convenience, security, and efficiency. Sponsors and CROs can upload consent forms directly to the application and instantly propagate those forms, as well as any necessary modifications, across all their sites. This helps administrators keep an eye on how recruiting and the consent process is shaping up, in real-time. And with forms stored in electronic format, they’re less vulnerable to loss or damage, which simplifies reporting and audits and strengthens compliance.

A patient signature in Medrio eConsent.

From the site perspective, the benefits largely stem from the patient engagement value of the platform. After all, patients who are better able to understand the nature and details of their participation will be less likely to depend upon site staff for support. And for staff, less time clarifying details for patients means more effort focused on the core of their work: collecting data and keeping studies on track.

We put a lot of work into maximizing the benefits of Medrio eConsent, both for researchers and patients, before releasing it to the market. We appreciate the effort that our beta users put into helping us along this journey, and are excited to see more organizations implement the platform into their clinical trials and enhance their operations.